AlphAIAlphAI — Financial news for AI agents
mychesco.comOCT 112 min read$JNJ

Johnson & Johnson Psoriasis Drug Sustains Clearance at Two Years

Johnson & Johnson (JNJ) reported that its oral psoriasis drug, ICOTYDE, maintained skin clearance through 112 weeks in a Phase 3 study, with 89% of genital psoriasis patients and 60% of scalp psoriasis patients achieving complete clearance. The study, presented at a dermatology congress, showed improved outcomes in difficult-to-manage areas, with no new safety concerns identified. JNJ aims to differentiate ICOTYDE in the psoriasis treatment market with its oral delivery.

Original reporting
mychesco.com
Published Oct 11, 2026, 2:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 11, 2026, 4:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Johnson & Johnson Psoriasis Drug Sustains Clearance at Two Years — source image
Source · mychesco.com
Decision brief

The 30-second read

$JNJBullishMed
01

Why it matters

The data provides the first long‑term efficacy readout for ICOTYDE, a differentiated oral IL‑23 inhibitor.

02

Market read

Positive Phase 3 results could lift JNJ's stock and influence the dermatology therapeutic landscape.

03

What to watch

Reimbursement negotiations and potential competition from newer biologics could temper upside.

Relevance 9/10Novelty 9/10Timing: today

Background

Johnson & Johnson presented the data at the 2026 European Academy of Dermatology and Venereology Congress.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

Phase 3 ICONIC‑TOTAL trial shows ICOTYDE maintains clearance in hard‑to‑treat psoriasis areas through 112 weeks.

Expected impact

likely upside as market prices in durability of response.

Evidence & confidence

Two‑year clearance rates (89% genital, 60% scalp) exceed expectations, supporting revenue growth for JNJ's dermatology franchise.

Market effects

Sector

strengthens outlook for systemic psoriasis treatments and may pressure competitors' pipelines.

Regional

U.S. and European dermatology markets see potential demand boost.

Global

adds confidence to biotech investors tracking IL‑23 inhibitors.

Counterpoint

What could challenge this read

Long‑term safety still limited; investors may wait for broader label expansion before committing.

Key entities

  • Company
    Johnson & Johnson

    Developer of ICOTYDE.

  • Product
    ICOTYDE

    Oral peptide IL‑23 receptor antagonist for psoriasis.

Read at source← All news

Related articles

OCT 9
$JNJMed

ICONIC-LEAD: Icotrokinra Sustains Psoriasis Skin Clearance at 2 Years

Johnson & Johnson's icotrokinra (Icotyde) showed sustained skin clearance and itch improvement in moderate-to-severe plaque psoriasis patients over 2 years, according to phase 3 ICONIC-LEAD study data. At least 72% of patients achieved PASI 90 and 70% achieved IGA 0/1. The drug is approved in the US, Europe, Japan, and China for adults and adolescents.

hcplive.com2 min
OCT 9
$JNJMed

Johnson & Johnson's Icotyde Shows Strong Phase 3 Results for Pla

Johnson & Johnson (JNJ) reported positive phase 3 trial results for Icotyde (icotrokinra) in treating plaque psoriasis, with 72% of patients achieving PASI 90. JNJ offers a 1.95% dividend yield with a 55% payout ratio and a GF Score™ of 83. Despite a 34.1% premium to its GF Value™, the dividend is deemed sustainable. Insider and guru activity shows net selling.

gurufocus.com3 min
OCT 9
$JNJMed

Johnson & Johnson Announces New Two-Year Results from Phase 3 ICONIC-LEAD Study Evaluating ICOTYDE in Adults and Adolescents with Moderate-To-Severe Plaque Psoriasis

Johnson & Johnson presented two-year results from the Phase 3 ICONIC-LEAD study of ICOTYDE® in moderate-to-severe plaque psoriasis. Data showed high skin clearance rates and sustained symptom improvement with no new safety signals. 72% of patients achieved PASI 90, and 70% achieved IGA 0/1. The study included 684 participants, with 66 adolescents. ICOTYDE is approved in the U.S., Europe, Japan, and China for psoriasis treatment.

marketscreener.com2 min
OCT 9
$BSXMed

Boston sues J&J subsidiary over alleged patent infringement for cardiology device

Boston Scientific sued Johnson & Johnson subsidiary Atraverse Medical, alleging patent infringement by its Hotwire device. Boston claims Atraverse knew its actions infringed Patent '955 and seeks damages and an injunction. J&J acquired Atraverse in 2026. The electrophysiology ablation catheter market is growing at 11.1% CAGR, with J&J's Biosense Webster leading at 43.1% market share in 2025.

finance.yahoo.com2 min
OCT 9
$JNJMedAI 8/10

Johnson & Johnson reports at least 72% PASI 90

Johnson & Johnson (JNJ) reported that its oral psoriasis drug ICOTYDE maintained at least 72% PASI 90 response rates through week 112 in the Phase 3 ICONIC-LEAD trial. JNJ shares rose 0.40% to $257.50. Alumis (ALMS) is also developing a psoriasis drug, envudeucitinib, with a planned U.S. application in Q4 2026.

mugglehead.com2 min